Sr Group Director, Clinical Pharmacology Regeneron Pharmaceuticals Tarrytown, New York
Upon completion, participants will understand the different approaches used to determine susceptibility of SARS-CoV-2 variants to monoclonal antibody therapies. Participants also will understand the challenges in making dosage adjustment recommendations for monoclonal antibody therapies against SARS-CoV-2 variants with reduced susceptibility, as well as the information regulatory agencies have utilized for decision-making purposes.
Learning Objectives:
Upon completion, participants will understand the different approaches used to determine susceptibility of SARS-CoV-2 variants to monoclonal antibody therapies
Upon completion, participants will understand the challenges in making dosage adjustment recommendations for monoclonal antibody therapies against SARS-CoV-2 variants with reduced susceptibility
Upon completion, participants will understand information regulatory agencies have utilized for decision-making purposes
